Apollo Hospitals Enterprise Ltd vs Samrat Pharmachem Ltd

A side-by-side comparison of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) and Samrat Pharmachem Ltd (SAMRATPH) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Apollo Hospitals Enterprise Ltd leads APOLLOHOSP vs SAMRATPH on 9 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

66.10
P/E ratio
11.30
13.49
P/B ratio
1.18
0.23%
Dividend yield
0.38%
₹135.04
EPS
₹23.01

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

22.10%
Return on equity
9.91%
18.00%
Return on capital
13.00%
15.00%
EBITDA margin
4.00%
7.94%
Net margin
2.45%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
-2.33%
33.39%
Profit CAGR (3Y)

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.28L Cr
Market cap
₹82 Cr
₹25,228 Cr
Revenue
₹286 Cr
₹2,003 Cr
Net profit
₹7 Cr
0.90
Debt / equity
0.16
Apollo Hospitals Enterprise Ltd
  • + ["Company has delivered good profit growth of 77.8% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
  • ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
Samrat Pharmachem Ltd
  • + ["Stock is trading at 1.18 times its book value"]
  • ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 10.1% over past five years.", "Company has a low return on equity of 2.40% over last 3 years."]
Apollo Hospitals Enterprise Ltd full analysis Samrat Pharmachem Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.